| Literature DB >> 28096184 |
Malgorzata Wamil1,2, Sacha Bull3, James Newton2.
Abstract
Despite significant advancements in the field of cardiovascular imaging, transoesophageal echocardiography remains the key imaging modality in the management of valvular pathologies. This paper provides echocardiographers with an overview of the modern role of TOE in the diagnosis and management of valvular disease. We describe how the introduction of 3D techniques has changed the detection and grading of valvular pathologies and concentrate on its role as a monitoring tool in interventional cardiology. In addition, we focus on the echocardiographic and Doppler techniques used in the assessment of prosthetic valves and provide guidance for the evaluation of prosthetic valves. Finally, we summarise quantitative methods used for the assessment of valvular stenosis and regurgitation and highlight the key areas where echocardiography remains superior over other novel imaging modalities.Entities:
Keywords: 3D echocardiography; TOE; valvular disease
Year: 2017 PMID: 28096184 PMCID: PMC5428919 DOI: 10.1530/ERP-16-0034
Source DB: PubMed Journal: Echo Res Pract ISSN: 2055-0464
Echocardiographic parameters used for the determination of the severity of valvular regurgitation as per EACVI (19) and the British Society of Echocardiography (BSE) guidelines.
| Mitral | Colour flow jet area: large central jet or eccentric jet adhering, swirling and reaching the posterior wall of the LA | Systolic flow reversal in pulmonary veins | LA and LV dilated | |
| Aortic | VC width (cm) ≥0.6 | Jet width in LVOT-colour flow: large in central jets, variable in eccentric jets | Holodiastolic flow reversal in the upper part of descending and in abdominal aorta | LA and LV dilated |
| Tricuspid | VC width (cm) >0.7 | Jet area, central jets (cm2): >10 | Systolic flow reversal in hepatic veins | RA, RV, IVC dilated |
| Pulmonary | VC width, EROA, R Vol not defined | Jet width ratio: >50–65% | Systolic flow reversal in pulmonary arteries | RV dilated |
CW, continuous-wave; ERO, effective orifice area; LA, left atrium; LV, left ventricle; PHT, pressure half time; PW, pulse-wave; RA, right atrium; RF, regurgitation fraction; RV, right ventricle; R Vol, regurgitation volume; VC, vena contracta.
Echocardiographic analysis of the mitral valve prior, during and post Mitral Clip procedure using Everest criteria.
| Mitral leaflet coaptation length and depth | >2 mm and <11 mm respectively |
| Gap between leaflets | <10 mm |
| Width of flail leaflet | <15 mm |
| Mitral valve opening area | >4 cm2 |
| Leaflet thickness | <5 mm |
| Considerable calcification of the mitral annulus | Not present |
| Marked restriction of posterior leaflet | Not present |
| Lack of primary or secondary chordal support | Not present |
| Several significant regurgitates jets | Not present |
| The trans-septal puncture | 3.5 cm to 4 cm above the plane of the mitral annulus |
| The advancement of the dilator though the interatrial septum | |
| The navigation of the clip-delivery-system in the left atrium towards the mitral valve | |
| The positioning of the device within the mitral leaflet zone of prolapse or coaptation defect | |
| The adjustment of perpendicularity of the clip into the left ventricle | |
| The grasping of the anterior and posterior leaflet by the clip and the closure of the clip | |
| Reduction of the mitral valve regurgitation | |
| Exclusion of the mitral stenosis |
Figure 1A transoesophageal 3D zoom image of the mitral valve showing severe mitral stenosis. QLAB (Philips Medical System) software was used for post-processing of the 3D dataset. The anatomical MV area (MVA) measures 0.7 cm2.
Methods for calculating mitral valve area (MVA) in native mitral stenosis on TOE.
| Planimetry | ||
| • by 2D | Tracing the mitral orifice obtained from the TG basal SAX view. Contour of the inner mitral orifice including commissures when opened | Direct measure of MVA, flow independent. Requires technical expertise to position the measurement plane on the mitral orifice |
| • by 3D | Performed from the mid-oesophageal view. The 3D dataset is cropped by an arbitrary plane, parallel to the MV annulus and then is planimetered using post processing software | 3D TOE more accurate than 2D. Gold standard in the assessment of MS |
| Pressure gradient | Tracing the entire envelope of the CWD spectrum of mitral inflow, from the beginning of early diastolic flow (E wave) to the end of flow due to atrial contraction (A wave). Mean gradient from the traced contour of the diastolic mitral flow. Requires averaging values over 5–10 cycles in AF | Influenced by heart rate, cardiac output, and associated MR |
| Pressure half-time (P1/2) | MVA (cm2) = 220/P1/2 | Influenced by compliance of LA and LV. Severe AR underestimates severity of MS. Not accurate in diastolic dysfunction and AF |
| Deceleration time (DT) | MVA (cm2) = 759/DT (ms) | The same limitations as for using P1/2 method |
| Continuity equation | MVA (cm2) = (CSA LVOT (cm2) × VTI LVOT) (cm)/VTI MV (cm) | Independent from flow conditions. Multiple measurements required (source of errors). Not valid in severe AR and MR |
| Proximal isovelocity surface area (PISA) | MVA = (PISA × Velocity aliasing)/peak velocity transmitral | Technically difficult. Multiple measurements required. Angle correction is essential. Can be used in the presence of MR |
3D, three dimensional; AF, atrial fibrillation; AR, aortic regurgitation; CSA, cross sectional area; CWD, continuous-wave Doppler; DT, deceleration time; MR, mitral regurgitation; MVA, mitral valve area; P1/2, pressure half-time; PISA, proximal isovelocity surface area; TG SAX view, transgastric short axis view; VTI, velocity time interval.
Figure 2An approach to echocardiographic assessment of a prosthetic valve. A complete TOE examination of the prosthetic valves includes the following steps. Firstly, 2D imaging of the structure and the motion of leaflets or occlude should be recorded. The calcification on the leaflets or abnormal echo densities on the various components of the prosthesis and the valve sewing ring integrity and motion should be evaluated. Secondly, the measurement of trans-prosthetic gradients and valve effective orifice area (EOA) needs to be recorded. Thirdly, the location (central versus paravalvular) and severity of regurgitation should be assessed. Lastly, such supportive parameters as left ventricular size and systolic function and systolic pulmonary arterial pressure should be evaluated. Examples of the failing prosthetic valves: (A) 2D views: before and after closure of the paraprosthetic mitral valve leak; (B) 3D ‘en face’ view of a severely stenotic mitral valve bio-prosthesis.